Morrow_subbed 26/11/08 02:37 Page 23
Chemotherapy-induced Nausea and Vomiting
implications for public health, Prev Med, 1997;26:607–11. breast cancer, Br J Health Psychol, 2000;5:105–19. 66. Lyles JN, Burish TG, Krozely MG, Oldham RK, Efficacy of relaxation
20. Barsky AJ, Saintfort R, Rogers MP, Borus JF, Non-specific 43. Roscoe JA, Jean-Pierre P, Shelke AR, et al., The role of patients training and guided imagery in reducing the aversiveness of
medication side effects and the nocebo phenomenon, JAMA, response expectancies in side effect development and control, Curr cancer chemotherapy, J Consult Clin Psychol, 1982;50(4):509–24.
2002;287:622–7. Problems Cancer, 2006;30(2):40–98. 67. Troesch LM, Rodehaver CB, Delaney EA, Yanes B, The influence of
21. Crow R, Gage H, Hampson S, et al., The role of expectancies in 44. Roscoe JA, Bushunow P, Morrow GR, et al., Patient expectation is guided imagery on chemotherapy-related nausea and vomiting,
the placebo effect and their use in the delivery of healthcare, a strong predictor of severe nausea after chemotherapy: A Oncology Nursing Forum, 1993;20(8):1179–85.
Health Technology Assessment, 1999;3(3):1–96. University of Rochester Community Clinical Oncology Program 68. Zeltzer L, Kellerman J, Ellenberg L, Dash J, Hypnosis for reduction
22. Dolgin MJ, Katz ER, McGinty K, Siegel SE, Anticipatory nausea and study of patients with breast carcinoma, Cancer, 2004;101(11): of vomiting associated with chemotherapy and disease in
vomiting in pediatric cancer patients, Pediatrics, 1985;75(3): 2701–8. adolescents with cancer, J Adolesc Health Care, 1983;4:77–84.
547–52. 45. Morrow GR, Roscoe JA, Hickok JT, et al., Nausea and emesis: 69. Kellerman J, Zeltzer L, Ellenberg L, Dash J, Adolescents with
23. Andrykowski MA, Jacobsen PB, Marks E, et al., Prevalence, Evidence for a biobehavioral perspective, Support Care Cancer, cancer. Hypnosis for the reduction of the acute pain and anxiety
predictors, and course of anticipatory nausea in women receiving 2002;10:96–105. associated with medical procedures, J Adolescent Health Care,
adjuvant chemotherapy for breast cancer, Cancer, 1988;62(12): 46. Board T, Board R, The role of 5-HT3 receptor antagonists in 1983;4(2):85–90.
2607–13. preventing post-operative nausea and vomiting, AORN J, 70. Marchioro G, Azzarello G, Viviani F, et al., Hypnosis in the
24. Andrykowski MA, The role of anxiety in the development of 2006;83(1):209–20. treatment of anticipatory nausea and vomiting in patients
anticipatory nausea in cancer chemotherapy: A review and 47. Markman M, Progress in preventing chemotherapy-induced receiving cancer chemotherapy, Oncology, 2000;59(2):100–104.
synthesis, Psychosom Med, 1990;52(4):458–75. nausea and vomiting, Cleve Clin J Med, 2002;69(8):609–7. 71. DuHamel KN, Redd WH, Vickberg SM, Behavioral interventions in
25. Watson M, Anticipatory nausea and vomiting: broadening the 48. Grunberg SM, Deuson RR, Mavros P, et al., Incidence of the diagnosis, treatment and rehabilitation of children with cancer,
scope of psychological treatments, Support Care Cancer, chemotherapy-induced nausea and emesis after modern Acta Oncologica, 1999;38(6):719–34.
1993;1(4):171–7. antiemetics, Cancer, 2004;100(10):2261–8. 72. Morrow GR, Asbury R, Hammon S, et al., Comparing the
26. Montgomery GH, Tomoyasu N, Bovbjerg DH, et al., Patients' 49. Gershon MD, Review article: serotonin receptors and transporters effectiveness of behavioral treatment for chemotherapy-induced
pretreatment expectations of chemotherapy-related nausea are an – roles in normal and abnormal gastrointestinal motility, Aliment nausea and vomiting when administered by oncologists, oncology
independent predictor of anticipatory nausea, Ann Behavioral Med, Pharmacol Ther, 2004;20(Suppl. 7):3–14. nurses, and clinical psychologists, Health Psychol, 1992;11(4):
1998;20(2):104–9. 50. Gershon MD, Tack J, The serotonin signaling system: from basic 250–56.
27. Jacobsen PB, Andrykowski MA, Redd WH, et al., understanding to drug development for functional GI disorders, 73. Roscoe JA, Morrow GR, Hickok JT, et al., The efficacy of
Non-pharmacologic factors in the development of post-treatment Gastroenterology, 2007;132(1):397–414. acupressure and acustimulation wrist bands for the relief of
nausea with adjuvant chemotherapy for breast cancer, Cancer, 51. Tonini G, Vincenzi B, Santini D, New drugs for chemotherapy- chemotherapy-induced nausea and vomiting: A URCC CCOP
1988;61:379–85. induced nausea and vomiting: focus on palonosetron, Expert Opin multicenter study, J Pain Symptom Manage, 2003;26(2):731–42.
28. Andrykowski MA, Redd WH, Hatfield AK, Development of Drug Metab Toxicol, 2005;1(1):143–9. 74. Dundee JW, Yang J, McMillan C, Non-invasive stimulation of the
anticipatory nausea: a prospective analysis, J Consult Clin Psychol, 52. Liu Q, Yang Q, Sun W, et al., Discovery and characterization of P6 (NeiGuan) antiemetic acupuncture point in cancer
1985;53(4):447–54. novel tryptophan hydroxylase inhibitors that selectively inhibit chemotherapy, J R Soc Med, 1991;84:210–12.
29. Watson M, McCarron J, Law M, Anticipatory nausea and emesis, serotonin synthesis in the gastrointestinal tract, J Pharmacol Exp 75. Morrow GR, Appropriateness of taped versus live relaxation in the
and psychological morbidity: Assessment of prevalence among Ther, 2008;325(1):47–55. systematic desensitization of anticipatory nausea and vomiting in
out-patients on mild to moderate chemotherapy regimens, Br J 53. Tattersall FD, Rycroft W, Francis B, et al., Tachykinin NK1 receptor cancer patients, J Consult Clin Psychol, 1984;52:1098–9.
Cancer, 1992;66(5):862–6. antagonists act centrally to inhibit emesis induced by the 76. Kris MG, Hesketh PJ, Somerfield MR, et al., American Society of
30. Paul GL, Insight versus desensitization in psychotherapy two years chemotherapeutic agent cisplatin in ferrets, Neuropharmacology, Clinical Oncology guideline for antiemetics in oncology: update
after termination, J Consult Clin Psychol, 1966;31:333–48. 1996;35(8):1121–9. 2006, J Clin Oncol, 2006;24(18):2932–47.
31. Kirsch I, Specifying non-specifics: Psychological mechanisms of 54. de WR, Herrstedt J, Rapoport B, et al., Addition of the oral NK1 77. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al., Improved
placebo effects. In: Harrington A (ed.), The placebo effect: An antagonist aprepitant to standard antiemetics provides protection prevention of moderately emetogenic chemotherapy-induced
interdisciplinary exploration, Cambridge: Harvard University Press, against nausea and vomiting during multiple cycles of cisplatin- nausea and vomiting with palonosetron, a pharmacologically
1997:166–86. based chemotherapy, J Clin Oncol, 2003;21(22):4105–11. novel 5-HT3 receptor antagonist: results of a phase III, single-dose
32. Rescorla RA, Pavlovian Conditioning: It's not what you think, Am 55. Redd WH, Behavioral intervention for cancer treatment side trial versus dolasetron, Cancer, 2003;98(11):2473–82.
Psychol, 1988;43:151–60. effects, Acta Oncol, 1994;33(2):113–17. 78. Hesketh PJ, Grunberg SM, Herrstedt J, et al., Combined data from
33. Voudouris NJ, Peck CL, Coleman G, The role of conditioning and 56. Morrow GR, Hickok JT, Behavioral treatment of chemotherapy- two phase III trials of the NK1 antagonist aprepitant plus a 5-HT
verbal expectancy in the placebo response, Pain, 1990;43:121–8. induced nausea and vomiting, Oncology, 1993;7(12):83–9. antagonist and a corticosteroid for prevention of chemotherapy-
34. Stewart-Williams S, Podd J, The placebo effect: Dissolving the 57. Vasterling J, Jenkins RA, Tope DM, Burish TG, Cognitive distraction induced nausea and vomiting: effect of gender on treatment
expectancy versus conditioning debate, Psychol Bull, 2004;130: and relaxation training for the control of side effects due to cancer response, Support Care Cancer, 2006;14(4):354–60.
324–40. chemotherapy, J Behav Med, 1993;16(1):65–80. 79. Hesketh PJ, Grunberg SM, Gralla RJ, et al., The oral neurokinin-1
35. Kirsch I, Lynn SJ, Vigorito M, Miller RR, The role of cognition in 58. Eller LS, Guided imagery interventions for symptom management, antagonist aprepitant for the prevention of chemotherapy-induced
classical and operant conditioning, J Clin Psychol, 2004;60(4): Ann Rev Nursing Res, 1999;17:57–84. nausea and vomiting: a multinational, randomized, double-blind,
369–92. 59. Burish TG, Tope DM, Psychological techniques for controlling the placebo-controlled trial in patients receiving high-dose cisplatin –
36. Roscoe JA, Morrow GR, Hickok JT, et al., Biobehavioral Factors in adverse side effects of cancer chemotherapy: Findings from a the Aprepitant Protocol 052 Study Group, J Clin Oncol,
Chemotherapy Induced Nausea and Vomiting, J Nat Comprehensive decade of research, J Pain Symptom Manage, 1992;7(5):287–301. 2003;21(22):4112–19.
Cancer Network, 2008; in press. 60. Burish TG, Lyles JN, Effectiveness of relaxation training in reducing 80. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al., Addition of
37. Watson M, Meyer L, Thomson A, Osofsky S, Psychological factors adverse reactions to cancer chemotherapy, J Behav Med, the neurokinin 1 receptor antagonist aprepitant to standard
predicting nausea and vomiting in breast cancer patients on 1981;4(1):65–78. antiemetic therapy improves control of chemotherapy-induced
chemotherapy, Eur J Cancer, 1998;34(6):831–7. 61. Molassiotis A, Yung HP, Yam BMC, et al., The effectiveness of nausea and vomiting. Results from a randomized, double-blind,
38. Montgomery GH, Bovbjerg DH, Specific response expectancies progressive muscle relaxation training in managing placebo-controlled trial in Latin America, Cancer, 2003;97(12):
predict anticipatory nausea during chemotherapy for breast chemotherapy-induced nausea and vomiting in Chinese breast 3090–98.
cancer, J Consult Clin Psychol, 2001;69(5):831–5. cancer patients: A randomized controlled trial, Support Care 81. Warr DG, Hesketh PJ, Gralla RJ, et al., Efficacy and tolerability of
39. Morrow GR, Roscoe JA, Hickok JT, Nausea and Vomiting. In: Cancer, 2002;10:237–46. aprepitant for the prevention of chemotherapy-induced nausea
Holland JC (ed.), Psycho-oncology, New York: Oxford University 62. Luebbert K, Dahme B, Hasenbring M, The effectiveness of and vomiting in patients with breast cancer after moderately
Press, 1998:476–84. relaxation training in reducing treatment-related symptoms and emetogenic chemotherapy, J Clin Oncol, 2005;23(12):2822–30.
40. Hickok JT, Roscoe JA, Morrow GR, et al., Nausea and emesis improving emotional adjustment in acute non-surgical cancer 82. Herrstedt J, Herrstedt J, Antiemetics: an update and the MASCC
remain significant problems of chemotherapy despite prophylaxis treatment: a meta-analytical review, Psycho-oncology, 2001;10: guidelines applied in clinical practice, Nature Clinical Practice
with 5-hydroxytryptamine-3 antiemetics: A University of Rochester 490–502. Oncology, 2008;5(1):32–43.
James P. Wilmot Cancer Center Community Clinical Oncology 63. Sodergren KM, Guided Imagery. In: Snyder M (ed.), Independent 83. National comprehensive cancer network. National Comprehensive
Program Study of 360 cancer patients treated in the community, Nursing Interventions, New York: Wiley, 1992:103–24. Cancer Network Practice Guidelines: Antiemesis Panel 2008
Cancer, 2003;97:2880–86. 64. Van Fleet S, Relaxation and imagery for symptom management: Guidelines, 2008.
41. Colagiuri B, Roscoe JA, Morrow GR, et al., How do patient Improving patient assessment and individualizing treatment, Oncol 84. ASCO, Evidence-Based Prevention of CINV: What's New in ASCO
expectancies, quality of life, and postchemotherapy nausea Nurs Forum, 2000;27(3):501–10. Guidelines, J Support Oncol, 2008;6(2):71–2.
interrelate?, Cancer, 2008;113:654–61. 65. Burish TG, Carey MP, Krozely MG, Greco FA, Conditioned side 85. Vrabel M, Is ondansetron more effective than granisetron for
42. Montgomery GH, Pre-infusion expectations predict post-treatment effects induced by cancer chemotherapy: Prevention through chemotherapy-induced nausea and vomiting? A review of
nausea during repeated adjuvant chemotherapy infusions for behavioral treatment, J Consult Clin Psychol, 1987;55:42–8. comparative trials, Clin J Oncol Nurs, 2007;11(6):809–13.
US ONCOLOGY 23